IFW 1614

Certification under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to THE COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on May 11, 2006.

Brian W. Hameder (Reg. No. 45,613) _____
Name Signature

DOCKET: CU-4618

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan G. PIERZYNOWSKI et al.

Serial No.: 10/562,953 Group Art Unit:

Filed: December 30, 2005 Examiner: Sharon Latimer

For: USE OF ALPHA-KETOGLUTARIC ACID FOR THE TREATMENT OF MALNUTRITION OR HIGH PLASMA GLUCOSE CONDITION

THE COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of the first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Date: May 11, 2006

_____
Signature of Attorney
Brian W. Hameder
Ladas & Parry LLP
224 South Michigan Avenue
Chicago Illinois 60604
Tel. No. (312) 427-1300
Reg. No. 45613

Certification under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to THE COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on May 11, 2006.

Brian W. Hameder (Reg. No. 45,613)
Name

Signature

DOCKET: CU-4618

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan G. Pierzynowski et al.

Serial No.: 10/562,953 Group Art Unit:

Filed: December 30, 2005 Examiner: Sharon Latimer

For: USE OF ALPHA-KETOGLUTARIC ACID FOR THE TREATMENT OF MALNUTRITION OR HIGH PLASMA GLUCOSE CONDITION

THE COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith patents, publications or other information of which the applicants are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose under 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

The references submitted herein are listed on PTO-1449 form (modified) enclosed herewith. A copy of each reference listed is being furnished except any duplicate or cumulative patents or publications specified otherwise. Also, if the present application was filed after June 30, 2003, copies of US patents or published applications are not submitted in accordance with the USPTO Rule changes.

A translation of any foreign language reference, if any, is indicated in PTO-1449 form and being submitted herein if it is readily available. Otherwise it should be construed that such translation is not readily available.

Additional comments, if any, on the relevance of each reference listed are provided as follows:

Also submitted herein is a copy of the PCT Search Report which satisfies the requirement for a translation or concise explanation of any non-English reference cited therein, as provided in MPEP §609 A(3).

The Statement is made on the basis of the information:

_____ supplied by the inventor(s);
__X__ supplied by an individual associated with the filing and prosecution of this application (37 CFR 1.56(c)); or
_____ in the attorney's file.

Respectfully submitted,



Date: May 11, 2006

Signature of Attorney
Brian W. Hameder
Ladas & Parry LLP
224 South Michigan Avenue
Chicago Illinois 60604
Tel. No. (312) 427-1300
Reg. No. 45613

Form **PTO-1449** (Modified)

FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	CU-4618	10/562,953
	APPLICANT: Stefan G. PIERZYNOWSKI et al	
	FILING DATE: December 30, 2005	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT DOCUMENT	ISSUE/PUB DATE	PATENTEE	CLASS	SUB-CLASS	FILING DATE
	5,124,314	06/23/92	Cooper			
	5,175,145	12/29/92	Cooper			
	5,234,906	08/10/93	Young et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB-CLASS	TRANSLATION YES	NO
	WO9310146	05/27/93	PCT				
	EP 0922459	06/16/99	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of publication)

	Windmueller, H.G., & Spaeth, A.E. (1975) Intestinal metabolism of glutamine and glutamate from the lumen as compared to glutamine from blood. Arch. Biochem. Biophys. 171: 662-672.
	Stoll, B., Burrin, D.G., Henry, J., Hung, Y., Jahoor, F., & Reeds, P.J. (1999) Substrate oxidation by the portal drained viscera of fed piglets. Am. J. Physiol. 227: E168-E175.
	Matthews, D.E., Marano, M.A., & Campbell, R.G. (1993) Splanchnic bed utilization of glutamine and glutamic acid in humans. Am. J. Physiol. 264: E848-E854.
	Madej, M., Lundh, T. & Lindberg, J.E. (1999) Activities of enzymes involved in glutamine metabolism in connection with energy production in the gastrointestinal tract epithelium of newborn, suckling and weaned piglets. Biol. Neonate 75: 250-258.
	Suryawan, A., Hawes, J.W., Harris, R.A., Shimomura, Y., Jenkins, A.E., & Hutsun, S.M. (1998) A molecular model of human branched-chain amino acid metabolism. Am. Clin. J. Nutr. 68: 72-81.
	Lambert, B.D., Stoll, B., Niinikoski, H., Pierzynowski, S., & Burrin, D.G. (2002) Net portal absorption of enterally fed alpha-ketoglutarate is limited in young pigs. J. Nutr. 132: 3383-3386.
	Kristensen, N.B., Jungvid, H., Fernandez, J.A., & Pierzynowski, S.G. (2002) Absorption and metabolism of α-ketoglutarate in growing pigs. *J. Anim. Physiol. A. Anim. Nutr* 86: 239-245.
	Bergmeyer, H.U., & Bernt, E. (1974) 2-oxoglutarate. UV spectrophotometric determination. In: Methods of enzymatic analysis, 2nd Ed. (Bergmeyer, H.U., ed). Academic Press, New York, NY.
	Pajor, A.M. (1999) Sodium-coupled transporters for krebs cycle intermediates. Annu. Rev. Physiol. 61: 663-682.
	Murphy, J.M., Murch, J.M., and Ball, R.O. (1996) Proline is synthesized from glutamate during intragastric infusion but not during intravenous infusion in neonatal piglets. J. Nutr. 126: 878-886.
	Riedel, Eberhard. (1996) α-Ketoglutarate Application in Hemodialysis Patients Improves Amino Acid Metabolism. Nephron 74: 261-265.

(Form PTO-1449)